STOCK TITAN

Viking Global boosts disclosure of 6.8% BridgeBio (BBIO) ownership stake

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Viking Global Investors and affiliated funds filed Amendment No. 10 to their Schedule 13D on BridgeBio Pharma, Inc. common stock. The reporting group discloses beneficial ownership of 13,026,367 shares, representing 6.8% of BridgeBio’s common stock, with shared voting and dispositive power over all reported shares.

The ownership percentage is calculated from 192,708,813 BridgeBio shares outstanding as of October 21, 2025, less 1,081,825 shares repurchased on January 21, 2026. The amendment updates the identity and structure of the Viking entities and individuals that may be deemed to share authority over this position and notes that recent transactions are listed in an attached exhibit.

Positive

  • None.

Negative

  • None.





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
All share percentage calculations in this Amendment No. 10 to the Schedule 13D are based on the difference between (i) 192,708,813 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of October 21, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on October 29, 2025, and (ii) 1,081,825 shares of Common Stock that the Issuer repurchased on January 21, 2026, as reported in the Issuer's current report on Form 8-K filed with the Commission on January 21, 2026.


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


VIKING GLOBAL INVESTORS LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)(3)
Date:02/17/2026
Viking Global Opportunities Parent GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3)
Date:02/17/2026
Viking Global Opportunities GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3)
Date:02/17/2026
Viking Global Opportunities Portfolio GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3)
Date:02/17/2026
Viking Global Opportunities Illiquid Investments Sub-Master LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)(3)
Date:02/17/2026
HALVORSEN OLE ANDREAS
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of HALVORSEN OLE ANDREAS (1)
Date:02/17/2026
Ott David C.
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Ott David C. (2)
Date:02/17/2026
Shabet Rose Sharon
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Shabet Rose Sharon (3)
Date:02/17/2026
Comments accompanying signature:
(1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).

FAQ

What ownership stake does Viking report in BridgeBio Pharma (BBIO) in Amendment No. 10?

Viking and its affiliated entities report beneficial ownership of 13,026,367 BridgeBio Pharma common shares, representing 6.8% of the company. This percentage is based on BridgeBio’s reported outstanding shares adjusted for a January 21, 2026 share repurchase disclosed in a Form 8-K.

Which entities are included as reporting persons in the BridgeBio (BBIO) Schedule 13D/A?

The filing is made jointly by Viking Global Investors LP, several Viking Global Opportunities entities, Viking Global Opportunities Illiquid Investments Sub-Master LP, and individuals O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet. They have a joint filing agreement dated February 17, 2026 governing this Schedule 13D amendment.

How did Viking calculate its 6.8% beneficial ownership of BridgeBio (BBIO)?

The 6.8% ownership is calculated using 192,708,813 BridgeBio common shares outstanding as of October 21, 2025, minus 1,081,825 shares repurchased on January 21, 2026. Viking’s 13,026,367 shares are then compared to this adjusted share count to determine the reported percentage.

Who ultimately controls voting and disposition of Viking’s BridgeBio (BBIO) shares?

The shares are directly held by Viking Global Opportunities Illiquid Investments Sub-Master LP, with voting and dispositive power flowing through Viking Global Opportunities Portfolio GP, Viking Global Opportunities GP, Viking Global Opportunities Parent GP, and Viking Global Investors LP. Certain executives, including O. Andreas Halvorsen, may be deemed to share this authority.

Does the Viking Schedule 13D/A for BridgeBio (BBIO) disclose recent trading activity?

The amendment states that, except for transactions listed in Exhibit 99.11, the reporting persons have not traded BridgeBio common stock in the past 60 days. The detailed schedule of those transactions appears in Exhibit 99.11 attached to the amendment, not in the main body.

What is the purpose of Viking’s Schedule 13D/A Amendment No. 10 on BridgeBio (BBIO)?

Amendment No. 10 updates prior Schedule 13D disclosures regarding Viking’s BridgeBio stake, including current beneficial ownership, the structure and roles of Viking entities and individuals, and a schedule of recent transactions. It also restates identification and background information for all reporting persons involved.
Bridgebio Pharma

NASDAQ:BBIO

BBIO Rankings

BBIO Latest News

BBIO Latest SEC Filings

BBIO Stock Data

14.42B
166.55M
Biotechnology
Pharmaceutical Preparations
Link
United States
PALO ALTO